Skip to main content
OpenTrials
Completed

NCT Number: NCT02781857

Mass Spectral Fingerprinting in Lung Cancer

To answer the question whether a disease specific profile of breath in patients with lung cancer can be detected by an untargeted metabolomic study using exhaled breath analysis by mass spectrometry.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Lung Cancer Lung Diseases Lung Neoplasms Neoplasms Neoplasms by Site Respiratory Tract Diseases Respiratory Tract Neoplasms Thoracic Neoplasms

Age range

18 year–85 year

Sex eligibility

All sexes

Study type

Observational

Primary location

University Hospital Zurich, Division of Pneumology

Zurich, Canton of Zurich, 8091, Switzerland

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Confirmed lung cancer based on cytological or histological analysis.
  • Group A: any type of lung cancer eligible for surgical resection (up to TNM stage IIIa).
  • Group B: any type of lung cancer (small-cell carcinoma, non-small-cell carcinoma) not amenable for surgical resection.
  • Group C: matched controls.
  • Age between 18 and 85 years at study entry

Exclusion criteria

  • Another 'active' secondary malignant disease (e.g. breast cancer, colon carcinoma) in group A and B, presence of any active malignant disease in group C (based on personal information).
  • Acute inflammatory disease (e.g. common cold) within the last 4 weeks.
  • Any other acute lung disease which affects breath measurements
  • Acute or chronic hepatic disease.
  • Renal failure or renal replacement therapy.

Treatment and study plan

No intervention

Other

Primary outcomes

  1. Concentration of volatile organic compounds (VOCs) in the exhaled breath will be analysed using mass spectrometry

    Time frame: 1 day, single measurement

    The primary outcome will be the lung cancer specific mass spectrometric profile of VOCs of exhaled breath analysis (markers of lung cancer in exhaled breath).

Secondary outcomes

  1. Group A: Concentration of volatile organic compounds (VOCs) in the exhaled breath will be analysed using mass spectrometry before and after lung cancer surgery

    Time frame: Group A: 2 measurements on 2 different days; Day 1: 1. measurement (before surgery), Day 2: (6-12 weeks after surgery): 2. measurement

    The acquired profiles of mass spectral VOCs before and after lung cancer surgery will be analysed for significant differences.

Sponsors and collaborators

Lead sponsor

University of Zurich

Other

Collaborators

  • Swiss Federal Institute of Technology

Registry information

Official study title

Exhaled Breath Analysis by Secondary Electrospray Ionization - Mass Spectrometry (SESI-MS) in Patients With Lung Cancer

Important dates

Study start
2016
Primary completion
2024
Study completion
2024
First posted
May 25, 2016
Registry last updated
Jun 1, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.